X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
KWA 0711 (mizagliflozin) is an investigational first-in-class, oral, SGLT1 inhibitor, small molecule drug candidate. It is being evaluated for the treatment of post-bariatric hypoglycemia.
Lead Product(s): Mizagliflozin
Therapeutic Area: Endocrinology Product Name: KWA 0711
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2024
Details:
KWA-0711 (mizagliflozin) is a novel first in class SGLT1 inhibitor, small molecule therapeutic candidate. It is being evaluated for the treatment of post-bariatric hypoglycemia.
Lead Product(s): Mizagliflozin
Therapeutic Area: Endocrinology Product Name: KWA-0711
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2024
Details:
Mizagliflozin Encapsulated or Liquid Formulation is a novel first in class small molecule therapeutic candidate being developed for Post-Bariatric Hypoglycemia.
Lead Product(s): Mizagliflozin
Therapeutic Area: Endocrinology Product Name: VGX-3235
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
